142 related articles for article (PubMed ID: 17509164)
1. Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.
Schneeweiss A; Lauschner I; Ruiz A; Guerrero A; Sánchez-Rovira P; Seguí MA; Goerke K; Wolf M; Manikhas AG; Wacker J; Marmé F; Lichter P; Sinn HP; Sohn C; Mansouri K; Bauknecht T; Hahn M
Clin Breast Cancer; 2007 Apr; 7(7):555-8. PubMed ID: 17509164
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Schneeweiss A; Marmé F; Ruiz A; Manikhas AG; Bottini A; Wolf M; Sinn HP; Mansouri K; Kennedy L; Bauknecht T
Ann Oncol; 2011 Mar; 22(3):609-617. PubMed ID: 20732932
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
von Minckwitz G; Raab G; Caputo A; Schütte M; Hilfrich J; Blohmer JU; Gerber B; Costa SD; Merkle E; Eidtmann H; Lampe D; Jackisch C; du Bois A; Kaufmann M
J Clin Oncol; 2005 Apr; 23(12):2676-85. PubMed ID: 15837982
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
5. CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.
Marmé F; Werft W; Walter A; Keller S; Wang X; Benner A; Burwinkel B; Sinn P; Hug S; Sohn C; Bretz N; Moldenhauer G; Rupp C; Rupp AK; Biakhov MY; Bottini A; Friedrichs K; Khailenko VA; Manikhas GM; Ruiz A; Sánchez-Rovira P; Santoro A; Segui MA; Villena C; Lichter P; Kristiansen G; Altevogt P; Schneeweiss A
Breast Cancer Res Treat; 2012 Apr; 132(3):819-31. PubMed ID: 21960110
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
7. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
Evans TR; Yellowlees A; Foster E; Earl H; Cameron DA; Hutcheon AW; Coleman RE; Perren T; Gallagher CJ; Quigley M; Crown J; Jones AL; Highley M; Leonard RC; Mansi JL
J Clin Oncol; 2005 May; 23(13):2988-95. PubMed ID: 15860854
[TBL] [Abstract][Full Text] [Related]
8. Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer.
O'Regan RM; Von Roenn JH; Carlson RW; Malik U; Sparano JA; Staradub V; Khan S; Jovanovic B; Morrow M; Gradishar WJ
Clin Breast Cancer; 2005 Jun; 6(2):163-8. PubMed ID: 16001995
[TBL] [Abstract][Full Text] [Related]
9. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
10. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Bear HD; Anderson S; Brown A; Smith R; Mamounas EP; Fisher B; Margolese R; Theoret H; Soran A; Wickerham DL; Wolmark N;
J Clin Oncol; 2003 Nov; 21(22):4165-74. PubMed ID: 14559892
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
12. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
Diéras V; Fumoleau P; Romieu G; Tubiana-Hulin M; Namer M; Mauriac L; Guastalla JP; Pujade-Lauraine E; Kerbrat P; Maillart P; Pénault-Llorca F; Buyse M; Pouillart P
J Clin Oncol; 2004 Dec; 22(24):4958-65. PubMed ID: 15611510
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.
Puhalla S; Mrozek E; Young D; Ottman S; McVey A; Kendra K; Merriman NJ; Knapp M; Patel T; Thompson ME; Maher JF; Moore TD; Shapiro CL
J Clin Oncol; 2008 Apr; 26(10):1691-7. PubMed ID: 18316792
[TBL] [Abstract][Full Text] [Related]
15. Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer.
Amat S; Mouret-Reynier MA; Penault-Llorca F; Leheurteur M; Delva R; Coudert B; Leduc B; Dauplat J; Curé H; Chollet P
Clin Breast Cancer; 2006 Aug; 7(3):262-9. PubMed ID: 16942644
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
Ramaswamy B; Povoski SP; Rhoades C; Allen J; Hauger M; Young D; Burak W; Farrar W; Yee L; Kendra K; Somasundaram S; Orlowski RZ; Shapiro CL
Breast Cancer Res Treat; 2005 Sep; 93(1):67-74. PubMed ID: 16184461
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer.
Lee KS; Ro J; Nam BH; Lee ES; Kwon Y; Kwon HS; Chung KW; Kang HS; Kim EA; Kim SW; Shin KH; Kim SK
Breast Cancer Res Treat; 2008 Jun; 109(3):481-9. PubMed ID: 17653851
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.
Vriens BE; Aarts MJ; de Vries B; van Gastel SM; Wals J; Smilde TJ; van Warmerdam LJ; de Boer M; van Spronsen DJ; Borm GF; Tjan-Heijnen VC;
Eur J Cancer; 2013 Oct; 49(15):3102-10. PubMed ID: 23850450
[TBL] [Abstract][Full Text] [Related]
20. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Pierga JY; Delaloge S; Espié M; Brain E; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Spielmann M; Savignoni A; Marty M
Breast Cancer Res Treat; 2010 Jul; 122(2):429-37. PubMed ID: 20480225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
